TRIPOD Checklist: Prediction Model Development and Validation

Section	Item		Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract					
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Page 1, Line 1-3	Title
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	Page 2-3, Line 6-38	Abstract
Introduction					
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Page 4-7, Line 67-109	Paragrph 1-2 of introduction
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	Page 7, Line 110-128	Paragrph 3 of introduction
Methods					
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, ifapplicable.	Page 8-9, Line 127-148	Methodology 2.1
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	Page 8, Line 133-134	Methodology 2.1
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	Page 11,Line 200-207;Page 16, Line 310-312	Methodology 2.2.3;Methodology 2.3.3
	5b	D;V	Describe eligibility criteria for participants.	Page 11,Line 207-209;Page 16, Line 310-312	Methodology 2.2.3;Methodology 2.3.3
	5c	D;V	Give details of treatments received, if relevant.	N/A, no treatment	N/A, no treatment
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	Page 13-14, Line 246-271; Page 17, Line 329-340	Methodology 2.2.5;Methodology 2.3.4
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	N/A, no need to blind assessment	N/A, no need to blind assessment
Predictors	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	Page 9-11, Line 151-198	Methodology 2.2.1; Methodology 2.2.2
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	N/A, no need to blind	N/A, no need to blind
Sample size	8	D;V	Explain how the study size was arrived at.	Page 11, Line 200-207;	Methodology 2.2.3;

Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	N/A, not an individual prognosis or diagnosis	N/A, not an individual prognosis or diagnosis
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	Page 17-18, Line 342-350	Methodology 2.3.5
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	Page 12-13, Line 233-243; Page 15-16, Line 296-308	Methodology 2.2.4; Methodology 2.3.2
	10c	V	For validation, describe how the predictions were calculated.	Page 13-14, Line 244-271;	Methodology 2.2.4;
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Page 13-14, Line 244-271;	Methodology 2.2.4;
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	N/A, no model updating	N/A, no model updating
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	N/A, no risk	N/A, no risk
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	Page 12, Line 231-232；	the second paragraph of Methodology 2.2.3
Results					
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	Page 11, Line 205-207; Page 15, Line 310-311;	Methodology 2.2.3; Methodology 2.3.3
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	Page 11, Line 205-207; Page 15, Line 310-311;	Methodology 2.2.3; Methodology 2.3.3
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	N/A, no comparison	N/A, no comparison
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	Page 19-20, Line 369-381	Results 3.2
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	N/A, not included	N/A, not included
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	N/A, not included	N/A, not included
	15b	D	Explain how to the use the prediction model.	Page 16, Line 296-308	Methodology 2.3.2
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	Page 20-21, Line 382-397	Second paragraph of Results 3.2
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	N/A, no model updating	N/A, no model updating
Discussion					
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	Page 29, Line 555-570	Seventh paragraph of Discussion

Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	Page 23-28, Line 427-548	Third to fourth paragraph of Discussion
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	Page 23-25, Line 427-487	Third to sixth paragraph of Discussion
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	Page 22-23, Line 401-426	First and second paragraph
Other information					
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	N/A,The dataset has not been authorized for public	N/A,The dataset has not been authorized for public
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	Page 31, Line 608-613	Funds

* Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

Article information: https://dx.doi.org/10.21037/qims-23-9
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.